PROTACs based on Tubocapsenolide A as well as preparation and application of PROTACs
By designing PROTACs based on Tubocapsenolide A, using E3 ligase ligands, killing CRC cells and degrading PLK1 protein at low doses and low concentrations, solving the problems of existing drug resistance and recurrence, and the treatment of colorectal cancer New strategies are provided.
Patent Information
- Application Number
- CN202411072619.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-22
AI Technical Summary
Existing colorectal cancer treatment drugs are prone to drug resistance and tumor recurrence. Traditional drugs require high concentrations of inhibitory targets, and the affinity of natural products is low, making it difficult to effectively inhibit CRC cells.
A series of PROTACs based on Tubocapsenolide A were designed to degrade target proteins through an ‘event-driven’ mechanism using ligands of the E3 ligase CRBN, VHL, MDM2 or cIAP, thereby improving anti-CRC activity and degradation activity.
TA-N and TA-P significantly kill CRC cells, take effect at low doses, target and degrade PLK1 protein, providing a new CRC treatment strategy, distinguishing it from the traditional placeholding-driven inhibitory model.
Smart Images

Figure BDA0004981297750000021 
Figure BDA0004981297750000022 
Figure BDA0004981297750000023
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of chemical biology, and specifically relates to PROTACs based on Tubocapsenolide A and preparation and application thereof. Background Art
[0002] Colorectal cancer (CRC) is the third most common malignant tumor in the world, second only to lung cancer and breast cancer. In 2020, there were approximately 1.932 million new cases of colorectal cancer worldwide, accounting for 10% of all cancer cases, and it has become a huge health threat. 90% of CRC deaths are directly related to drug resistance and recurrence. Currently, the drugs approved for the treatment of CRC include chemotherapy drugs such as 5-fluorouracil, oxaliplatin and irinotecan, as well as targeted drugs such as vascular endothelial growth factor inhibitors and epidermal growth factor receptor inhibitors. Drug resistance and tumor recurrence are often accompanied during the treatment of CRC. Therefore, it is urgent to find innovative and effective clinical drugs for the treatment of colorectal cancer. Due to the diversity and structural complexity of scaffolds, natural products have long been the main source of new drugs for the treatment of infectious diseases and cancer. Tubocapsenolide A (TA) is a class of high-content withanolide compounds isolated from the plant of the genus Tubocapsenolide of the Solanaceae family. It exhibits strong cytotoxicity against a variety of tumor cells, especially CRC cells, and exhibits good antitumor activity against CRC cell xenografts.
[0003] The idea of protein-targeted chimeras has gradually entered the field of drug development, which uses the ubiquitination mechanism to degrade the target protein to achieve inhibition of the target protein. Traditional small molecules and antibodies inhibit the function of the target protein through a "placeholder-driven" mode of action to treat the disease. This mode of action requires inhibitors or monoclonal antibodies to have a high concentration to occupy the active site of the target and block the transduction of downstream signaling pathways. PROTAC works through an "event-driven" mechanism, does not affect protein function, and mediates the degradation of the target protein. Due to the multi-pathway and multi-target characteristics of natural products, the affinity between natural products and targets is often of moderate intensity. Therefore, applying the "event-driven" characteristics of PROTAC to natural products can promote their biological activity to a certain extent and discover a series of potential small molecule degraders with anti-CRC activity. Summary of the invention
[0004] The present invention utilizes Tubocapsenolide A as a lead compound and applies PROTAC technology to design and synthesize a series of small molecule degraders, aiming to provide PROTACs based on Tubocapsenolide A with anti-CRC activity and degradation activity, and provide their applications.
[0005] The present invention provides PROTACs based on Tubocapsenolide A (TA) as shown in the following formula I;
[0006]
[0007] Wherein, m is an integer between 0 and 10;
[0008] L is selected from any of the following structures:
[0009]
[0010] E3 is an E3 ubiquitin ligase ligand selected from one or more ligands corresponding to CRBN, VHL, MDM2 and cIAP;
[0011] Furthermore, the CRBN is preferably one of the following structural formulas:
[0012]
[0013] Wherein W is selected from CH 2 、C=O、SO 2 , one of NH and N-alkyl; the alkyl is preferably a C1-C4 alkyl;
[0014] X is selected from one of O and S;
[0015] Z is selected from one of hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl and halogen;
[0016] G and G' are each independently selected from H, C1-C4 alkyl, -OH and C1-C4 alkyl substituted 5-10 membered heterocyclic group, wherein the heterocyclic group contains 1-3 heteroatoms of N, O or S;
[0017] R 1 One selected from H, D, halogen, nitro, amino, cyano, hydroxyl, C1-C4 alkyl, halogenated C1-C4 alkyl and deuterated C1-C4 alkyl;
[0018] The structural formula of the VHL is:
[0019]
[0020] in:
[0021] R 2 Selected from CH 3 and one of H.
[0022] The structural formula of the MDM2 is:
[0023]
[0024] in:
[0025] R 3 It is a piperazinyl group, a piperidinyl group, a heterocyclic group or one of the following linking groups:
[0026]
[0027] In the linking group, n is an integer of 0-10;
[0028] The heterocyclic group is piperazinyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl.
[0029] The structure of the cIAP is:
[0030]
[0031] Furthermore, the general formula of PROTACs based on Tubocapsenolide A described in the present invention is selected from Formula II, Formula III, Formula IV and Formula V:
[0032]
[0033]
[0034] Wherein, m is an integer between 0 and 10; and n is an integer between 0 and 10.
[0035] The PROTACs based on Tubocapsenolide A described in the present invention are specifically selected from the following compounds:
[0036]
[0037]
[0038] The present invention also provides a method for preparing PROTACs based on Tubocapsenolide A, the route of which is as follows, comprising the following steps:
[0039]
[0040] Wherein, m is an integer between 0 and 10, and n is an integer between 0 and 10.
[0041] (1) Synthesis of TA-ester
[0042] TA, 6-heptynoic acid, EDCI and DMAP were added to dichloromethane and reacted at room temperature. After the reaction was completed, dichloromethane was added to the reaction system for extraction, and the organic phase was concentrated and distilled under reduced pressure to purify to obtain TA-ester.
[0043] (2)N 3 -Synthesis of L-E3
[0044] aN 3 -Synthesis of L-VH032:
[0045]
[0046] Compound VH032 was placed in a reaction flask, dichloromethane was added, and then DIPEA, EDCI and HOBt were reacted under ice bath conditions for 30 minutes, and then the reaction was continued at room temperature. After the reaction was completed by thin layer chromatography, the organic phase was extracted and concentrated, and then purified by vacuum distillation to obtain N 3 -L-VH032.
[0047] Bn 3 -Synthesis of L-Pomalidomide:
[0048]
[0049] The compound Pomalidomide was dissolved in DMF, and DIPEA was added to the reaction system. The reaction was continued at 90°C until the reaction was complete, and the organic phase was concentrated and distilled under reduced pressure to obtain compound N. 3 -L-Pomalidomide.
[0050] cN 3 -Synthesis of L-Nutlin-3:
[0051]
[0052] Dissolve Nutlin-3 in DCM, add EDCI, HOBt, DIPEA under ice bath, then add The reaction was completed, and the organic phase was extracted and concentrated, and the compound N was purified by vacuum distillation. 3 -L-Nutlin-3.
[0053] dN 3 -Synthesis of L-MeBS:
[0054]
[0055] Dissolve MeBS in DCM, add EDCI, HOBt, DIPEA under ice bath, then add The reaction was completed, and the organic phase was extracted and concentrated, and the compound N was purified by vacuum distillation. 3 -L-MeBS.
[0056] (3) Synthesis of TA-E3
[0057] TA-ester and the N prepared in step (2) 3 -L-E3 was dissolved in THF, and then H 2 O、CuSO 4 and sodium L-ascorbate, react at room temperature; after the reaction is completed by TLC, THF is removed by distillation under reduced pressure, dichloromethane is added to the residue, and H 2 O, the organic phase was collected and washed with anhydrous Na 2 SO 4 The crude product was purified by silica gel column chromatography.
[0058] Furthermore, in step (1), the molar ratio of TA:6-heptynoic acid:EDCI:DMAP is 1:(1.1-1.3):2:(0.04-0.06).
[0059] Further, in step (2), in molar ratio, VH032: DIPEA: EDCI: HOBt=1: (0.9~1.1): (1.3~1.7): (0.6~0.9): (1.1~1.5);
[0060] In terms of molar ratio, Pomalidomide:DIPEA:
[0061] In terms of molar ratio, MDM2: DIPEA: EDCI: HOBt=1: (1~1.1): (1.3~1.7): (1~1.1): (1~1.1);
[0062] In terms of molar ratio, Nutlin-3: DIPEA: EDCI: HOBt=1: (1~1.1): (1.3~1.7): (1~1.1): (1~1.1);
[0063] In molar ratio, MeBS:EDCI:HOBt:DIPEA:
[0064] Further, in step (3), TA-ester: N 3-L-E3: CuSO 4 :L-sodium ascorbate=1:(1.1~1.3):(1.1~1.3):(2.5~3.5), THF and H 2 The volume ratio of O is 1:1.
[0065] Use of PROTACs based on Tubocapsenolide A or a pharmaceutically acceptable salt thereof according to the present invention in the preparation of drugs for treating and / or preventing cancer.
[0066] Pharmaceutically acceptable salts of PROTACs based on Tubocapsenolide A of the present invention include addition salts formed by PROTACs based on Tubocapsenolide A and the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, etc. Hydrochloric acid, hydrobromic acid, sulfuric acid, citric acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, maleic acid, benzenesulfonic acid, succinic acid and similar known acceptable acid salts.
[0067] The present invention also includes prodrugs of the derivatives of the present invention, which may have weak or even no activity themselves, but after administration, they are converted into corresponding biologically active forms under physiological conditions (such as by metabolism, solvolysis or other means).
[0068] The present invention provides a pharmaceutical composition comprising the PROTACs of Tubocapsenolide A or a pharmaceutically acceptable salt thereof and one or more of a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
[0069] Furthermore, the dosage form of the pharmaceutical composition is injection, tablet or capsule.
[0070] The present invention also provides the use of the pharmaceutical composition in preparing drugs for treating and / or preventing cancer.
[0071] Furthermore, the cancer is one or more of colorectal cancer, bone cancer, lung cancer, gastric cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, bladder cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and skin cancer.
[0072] Beneficial effects of the present invention:
[0073] The purpose of the present invention is to provide a PROTACs based on TubocapsenolideA and its preparation and application in view of the deficiencies in the prior art, specifically, TA-PROTACs capable of driving different E3 ligases are synthesized and prepared based on TA and ligands of E3 ligases CRBN, VHL, MDM2 or cIAP. And its application in anti-CRC treatment is explained. Among them, TA-N and TA-P have obvious killing effects on CRC cells, and the effect is better than TA. In addition, TA-N induces PLK1 protein degradation in a time- and dose-dependent manner. Therefore, the design of small molecule degraders based on TA will provide a new strategy for CRC treatment.
[0074] The TA-PROTACs provided by the present invention effectively promote CRC cell death, target and degrade PLK1; similar to catalytic reactions, the drug has a low effective dose; only binding activity is provided, which is event-driven, different from traditional occupancy-driven, and does not require direct inhibition of the functional activity of the target protein; the drug does not need to bind to the target protein for a long time and with high intensity. The PROTACs based on TubocapsenolideA provided by the present invention provide a new treatment method for tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 The IC values of TA-P, TA-V, TA-N and TA-B for HCT116 cells are 50 .
[0076] Figure 2 The TA-N of the present invention has a dose- and time-dependent degradation effect on PLK1 protein. DETAILED DESCRIPTION
[0077] The scheme of the present invention is further described below by examples, which are not intended to limit the present invention. Unless otherwise specified, the experimental operations in the examples are all based on mature prior art in the biological field, and the raw materials and reagents used can be obtained commercially.
[0078] Example 1: TA-ester and N 3 Synthesis of -L-E3
[0079]
[0080] TA (100.0 mg, 0.21 mmol), 6-heptynoic acid (31.5 mg, 0.25 mmol), EDCI (80.5 mg, 0.42 mmol) and DMAP (5.0 mg, 0.04 mmol) were added to 5 mL of dichloromethane and reacted overnight at room temperature. After the reaction was completed, 25 mL of dichloromethane was added to the reaction system, and the organic phase was treated with H2 O for 2 times, 10 mL each time, and the organic phase was collected and washed with anhydrous Na 2 SO 4 After drying, the crude product was concentrated by distillation under reduced pressure and purified by silica gel column chromatography (dichloromethane:methanol=60:1, v / v) to obtain a white solid product with a yield of 66%.
[0081] 1 HNMR (600MHz, CDCl 3 )δ7.08(dd,J=9.8,6.1Hz,1H),6.26(d,J=9.8Hz,1H),4.69(d,J=6.1Hz,1H),4.37(m,1H),4.13(t,J=7.7Hz,1H),3.29(d ,J=2.0Hz,1H),2.49–2.41(m,2H),2.40–2.33(m,4H),2.19(m,3H),2.14(td,J=13.4,12.7,6.1Hz,3H),2.07–2.00(m,1H ),1.95(t,J=2.6Hz,1H),1.91(s,3H),1.86(d,J=2.2Hz,3H),1.75–1.70(m,2H),1.68(d,J=3.1Hz,1H),1.56–1.51(m,2H ),1.35(s,3H),1.31–1.26(m,1H),1.17(dd,J=12.4,4.7Hz,1H),1.12(s,3H),1.09–1.05(m,1H),0.97(d,J=7.4Hz,3H).
[0082] aN 3 -Synthesis of L-VH032:
[0083]
[0084] 215 mg of compound VH032 was placed in an eggplant-shaped flask, 3 mL of DCM was added, and 57.5 mg of 3-azidopropionic acid, 132 μL of DIPEA, 74 mg of EDCI and 92 mg of HOBt were added in sequence under an ice bath. After the reaction was completed at room temperature, 30 mL of water and 30 mL of DCM were added for extraction. The organic layer was dried over anhydrous sodium sulfate and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain 279 mg of a white solid (yield: 53%).
[0085] Bn 3 -Synthesis of L-Pomalidomide:
[0086]
[0087] Dissolve 1 eq of Pomalidomide in DMF, add 3 eq of DIPEA and 1 eq of
[0088] After reacting at 90°C for 2 hours, the mixture was diluted with water and extracted with ethyl acetate. The organic phase was collected, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain compound N 3 -L-Pomalidomide, yield 67%.
[0089] cN 3 -Synthesis of L-Nutlin-3:
[0090]
[0091] Take 1.0eq Nutlin-3 and dissolve it in DCM. Add 1.1eq EDCI, 1.1eq HOBt, 1.5eq DIPEA under ice bath, and then add 1.0eq After reacting for 5 h, an appropriate amount of DCM was added to dilute and extract, and the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain compound N 3 -L-Nutlin-3.
[0092] dN 3 -Synthesis of L-MeBS:
[0093]
[0094] Take 1eq MeBS and dissolve it in DCM. Add 1.1eq EDCI, 1.1eq HOBt, 1.5eq DIPEA in an ice bath, and then add 1eq After reacting for 2 h, an appropriate amount of DCM was added to dilute and extract, and the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain compound N 3 -L-MeBS.
[0095] Example 2: Synthesis of TA-P
[0096]
[0097] TA-ester (0.10 mmol) prepared in Example 1 and N 3 -L-Pomalidomide (0.12 mmol) was dissolved in THF (1 mL), and then water (1 mL), CuSO 4(0.13 mmol) and sodium L-ascorbate (0.30 mmol). After the reaction was completed by TLC detection, THF was removed by distillation under reduced pressure, 10 mL of dichloromethane was added to the residue, and H 2 O (3 mL * 2 times), the organic phase was collected and washed with anhydrous Na 2 SO 4 The crude product was purified by silica gel column chromatography (dichloromethane:methanol=20:1, v / v) to obtain a yellow solid product with a yield of 53%.
[0098] 1 HNMR (600MHz, CDCl 3 )δ8.36(s,1H),7.55(d,J=9.8Hz,1H),7.50(dd,J=8.5,7.1Hz,1H),7.11(d,J=7.1Hz,1 H),7.07(dd,J=9.8,6.1Hz,1H),6.92(d,J=8.5Hz,1H),6.26(d,J=9.8Hz,1H),4.95–4. 89(m,1H),4.68(d,J=6.1Hz,1H),4.51(d,J=5.0Hz,2H),4.34(s,1H),4.13(t,J=7.6Hz ,1H),3.87(t,J=4.7Hz,2H),3.72(t,J=5.3Hz,2H),3.67–3.59(m,9H),3.47(t,J=5.4Hz ,2H),3.28(s,1H),3.10(dd,J=7.3,4.8Hz,1H),2.89(d,J=14.2Hz,1H),2.80–2.71(m, 4H),2.48–2.38(m,3H),2.35(m,3H),2.20(m,1H),2.15–2.10(m,3H),2.03(m,1H),1.9 2(m,3H),1.86(d,J=2.4Hz,3H),1.66(d,J=12.6Hz,4H),1.33(s,3H),1.31–1.25(m,2H ),1.22(d,J=7.9Hz,1H),1.12(s,3H),1.10–1.04(m,1H),0.98(dd,J=13.8,6.7Hz,3H).
[0099] 13 CNMR (101MHz, CDCl 3)δ201.45,178.28,172.12,171.08,169.28,168.40,167.39,165.95,149.50,139.72,138.60,136.08,134 .60,133.54,131.12,122.53,121.68,117.28,112.55,110.32,82.22,78.67,71.88,70.76,70.64,70.57, 69.53,61.27,60.53,53.33,50.85,50.19,48.89,47.97,45.83,43.54,42.41,40.92,40.62,34.37,33.72,31.43,30.38,29.40,28.60,25.37,25.17,24.31,24.06,22.96,22.79,20.55,14.96,12.50,12.36,8.62.
[0100] Example 3: Synthesis of TA-V
[0101]
[0102] The synthesis method is as in Example 2 for the synthesis of TA-P; the difference is that N 3 -L-Pomalidomide replaced by N 3 -L-VH032.
[0103] 1 HNMR (600MHz, CDCl 3)δ8.71(s,1H),7.39–7.35(m,4H),7.07(dd,J=9.8,6.1Hz,1H),6.61(s,1H),6.26(d,J=9.7Hz,1H),5.09(t,J=6.9Hz,1H),4.77(s,1H),4.68(d,J=6.0Hz,1H),4.51(s,1H),4.41(s,1H),4.37(m,3H),4.13(t,J=7.6Hz,1H),4.07(s,1H),3.53(d,J=11.4Hz,1H),3.28(s,1H),2.71(s,2H),2.60–2.55(m,1H),2.52(s,3H),2.45(s,2H),2.40–2.31(m,5H),2.25(d,J=10.3Hz,1H),2.16(m,10H),2.04(m,2H),1.91(s,3H),1.85(d,J=2.7Hz,3H),1.67(s,4H),1.52(d,J=6.9Hz,3H),1.33(s,3H),1.30–1.28(m,1H),1.27–1.25(m,1H),1.12(s,3H),1.06(d,J=7.3Hz,2H),0.97(d,J=7.4Hz,3H),0.86(s,9H).
[0104] 13 CNMR(101MHz,CDCl 3 )δ201.25,172.53,172.07,169.61,166.31,149.78,143.09,140.28,138.98,134.58,133.79,129.54,126.74,121.69,82.19,78.68,77.23,71.94,70.06,61.26,60.54,58.33,58.14,56.65,53.29,49.84,47.98,47.18,43.54,42.52,40.90,40.63,35.73,34.73,34.31,33.76,32.49,32.00,31.83,30.38,29.68,29.41,29.22,28.51,26.59,26.40,26.04,25.35,25.21,24.33,24.06,22.95,21.97,20.56,15.92,14.97,12.47,12.36.
[0105] Example 4: Synthesis of TA-N
[0106]
[0107] The synthesis method is as in Example 2 for the synthesis of TA-P; the difference is that N 3 -L-Pomalidomide replaced by N 3 -L-MeBS.
[0108] 1 HNMR (600MHz, CDCl 3 )δ7.71–7.51(m,1H),7.09(m,5H),6.87(s,3H),6.64(m,1H),6.49(s,1H) ,6.25(dd,J=9.5,4.1Hz,1H),5.69(s,1H),4.68(d,J=5.8Hz,2H),4.37(m ,1H),4.12(s,1H),3.89(m,7H),3.63–3.48(m,12H),3.38(m,2H),3.29(s ,1H),3.18(s,1H),2.83–2.52(m,2H),2.49–2.29(m,7H),2.21–2.17(m,1 H),2.15–2.10(m,2H),2.03(d,J=17.4Hz,2H),1.91(s,3H),1.85(s,3H), 1.69(s,4H),1.42(d,J=8.4Hz,3H),1.37–1.32(m,6H),1.29(d,J=1.5Hz, 2H),1.26(d,J=6.9Hz,2H),1.23(d,J=8.7Hz,1H),1.16(dd,J=12.3,4.4Hz,1H),1.12(s,3H),1.08(d,J=10.1Hz,1H),0.96(dd,J=7.4,1.9Hz,3H).
[0109] 13 CNMR (101MHz, CDCl 3)δ201.23,172.51,167.69,166.33,162.93,153.71,151.48,149.79,1 48.43,144.21,140.39,139.02,138.24,134.59,133.82,133.11,128.9 7,128.12,124.40,123.86,121.69,119.07,116.39,105.12,98.23,82 .20,80.20,78.67,75.93,75.04,71.95,71.22,70.51,70.29,69.63,68 .58,66.67,66.05,63.92,61.28,60.58,57.32,55.89,53.29,50.09,48.00,46.78,43.55,42.69,42.42,40.98,40.67,39.28,36.75,34.26,33.84,33.00,31.91,31.43,30.40,30.19,29.69,29.31,27.26,25.39,24.43,24.07,23.42,22.96,22.61,20.59,15.06,13.92,12.44,12.38.
[0110] Example 5: Synthesis of TA-B
[0111]
[0112] The synthesis method is as in Example 2 for the synthesis of TA-P; the difference is that N 3 -L-Pomalidomide replaced by N 3 -L-Nutlin-3.
[0113] 1 HNMR (600MHz, CDCl 3)δ7.33(d,J=8.7Hz,2H),7.28(d,J=7.8Hz,1H),7.26(s,1H),7.21(m,4H),7.08(dd,J=9.8,6.1Hz,1H),6.25(dd,J=9.6,3.8Hz,2H),4.68(d,J=6.1Hz,1H),4.60–4.54(m,1H),4.37(m,1H),4.32(s,2H),4.20–4.16(m,2H),4.13(t,J=7.6Hz,1H),3.72(s,3H),3.29(d,J=1.9Hz,1H),3.08(t,J=8.4Hz,2H),2.77–2.68(m,2H),2.45–2.32(m,6H),2.19(dd,J=17.7,3.4Hz,1H),2.17–2.09(m,3H),2.05(td,J=7.7,5.6Hz,2H),1.91(s,3H),1.86–1.85(m,3H),1.72–1.62(m,6H),1.61–1.56(m,2H),1.46(t,J=7.4Hz,2H),1.34(s,3H),1.32–1.28(m,6H),1.25–1.17(m,8H),1.12(s,3H),0.97(d,J=7.4Hz,3H),0.92(d,J=6.2Hz,3H),0.90(d,J=6.2Hz,3H).
[0114] 13 CNMR(101MHz,CDCl 3 )δ201.22,175.53,172.76,172.52,166.36,149.78,140.30,139.02,138.01,134.56,133.77,129.19(2),128.54(2),126.67,121.70,82.20,78.68,77.23,73.82,71.91,69.74,68.07,64.21,61.26,60.52,56.09,53.28,52.31,50.40,47.97,43.55,42.78,42.67,41.19,40.90,40.64,39.18,36.38,35.55,34.27,33.79,30.39,30.18,29.24,29.18,29.14,29.06,28.90,26.53,25.49,25.32,24.79,24.37,24.05,22.95,22.88,21.65,20.56,14.96,12.44,12.36.
[0115] Example 6: CCK8 detection of PROTACs cytotoxicity to HCT116 cells
[0116] (1) HCT116 cells in good logarithmic growth state and in the logarithmic growth phase were selected, counted using a cell counter, and diluted to 8000 cells / 100 μL. The cell suspension was evenly added to 96-well plates using a pipette and placed at 37°C and 5% CO. 2 The plates were incubated in a constant temperature incubator for 24 h. After 24 h, the culture medium containing different concentrations of TA-PROTACs was added to the 96-well plate and placed in a 37°C, 5% CO 2 Culture in a constant temperature incubator for 24 hours.
[0117] (2) After the drug effect ended, 10 μL of CCK8 solution (10 mg / mL) was added to each cavity and placed at 37°C and 5% CO 2 The cells were cultured in a constant temperature incubator for 1-4 h. After incubation, the absorbance (OD value) of each well was measured at a wavelength of 490 nm using an enzyme reader.
[0118] Cell survival rate (%) = (OD value 加药组 -OD value 空白组 ) / (OD value 对照组 -OD value 空白组 )×100%
[0119] like Figure 1 The experimental results showed that compounds TA-V, TA-P, TA-N and TA-B showed significant cytotoxicity to HCT116 cells, among which TA-P and TA-N had an IC 50 The killing effect of TA on HCT116 cells was better than that of TA (IC 50 :0.661±0.026μM).
[0120] Example 7: Western Blot detection of PLK1 protein degradation
[0121] (1) Digest and collect cells that have grown logarithmically and have reached a fusion degree of 90%, add fresh culture medium to adjust the cell concentration, and then count them using a cell counting plate. Evenly inoculate the cells in a large dish, culture them in an incubator until they adhere to the wall and begin to enter the logarithmic division phase, replace the medium containing drugs and continue to culture in the incubator for 48 hours. After waiting for the end of the culture, use trypsin to digest the cells and collect them, and mark them. Wash them twice with PBS to remove the excess EDTA in the trypsin, each time for 5 minutes, and collect the cells in a 1.5mL EP tube. After washing, add an appropriate amount of RIPA lysis buffer according to the number of cells, add phosphatase inhibitors and whole enzyme inhibitors to the lysis buffer in advance, and add PMSF in time. PMSF is an irreversible inhibitor of serine proteases that can inhibit serine proteases (trypsin and chymosin), as well as cysteine proteases and acetylcholinesterase, thereby preventing protein degradation. After adding the lysis buffer, use a vortex oscillator to mix the cells, and lyse the proteins on ice to prevent protein degradation. Lyse on ice for 20 minutes. After lysis, centrifuge at 4°C at 11,500 rpm for 10 min. Wait for the centrifugation to end and aspirate the supernatant, which is the protein.
[0122] (2) This experiment uses the BCA method to detect protein content. Under alkaline conditions, protein converts Cu 2+ Reduction to Cu + , Cu + It forms a purple-blue complex with the BCA reagent, and its absorbance at 562nm is measured and compared with the standard curve to calculate the concentration of the protein to be tested;
[0123] (3) Add the corresponding volume of 6×Loading buffer to the quantified protein sample according to its volume. Add DTT to the 6×Loading buffer before use. DTT can open the disulfide bond on cys, which makes it easier for the antibody to recognize and bind to specific sites. Use a vortex oscillator to mix the sample and put it in a 100°C water bath for 5-10 minutes to fully denature the protein. If the amino acid composition of a protein contains more hydrophobic amino acids (tryptophan W, alanine A, valine V, leucine L, isoleucine I, proline P, phenylalanine F, etc.), the protein is very hydrophobic and it is easy for the protein to form aggregates after boiling. For such a protein rich in hydrophobic amino acids, it can be incubated at 37°C for 1 hour, or 60°C for 30 minutes instead of boiling in a 100°C water bath for 5-10 minutes;
[0124] (4) preparing SDS-PAGE gel and loading the prepared samples;
[0125] (5) Place the PVDF membrane in anhydrous methanol for 30 seconds to activate the PVDF membrane. Then soak the membrane in wet transfer solution. Place the sponge, filter paper and PVDF membrane in the electroporation clip in turn, and then put the glue, filter paper and sponge in turn to make a sandwich structure. Avoid bubbles between the glue and the membrane. Insert the sandwich structure into the electroporation tank and place the electroporation device in an ice box mixed with ice and water to avoid excessive heat during the transfer process, which may cause transfer failure. Use 300mA to transfer protein for 2 hours;
[0126] (6) After the protein transfer is completed, the sandwich structure is opened, the membrane is stained with Lichunhong to check the transfer effect, and the membrane is cleaned with pure water. The membrane is cut according to the molecular weight of the protein, and the PVDF membrane is dried with filter paper and activated again with methanol. After activation, the surface methanol is cleaned with pure water, and then placed in 5% skim milk and blocked on a shaker for 2 hours;
[0127] (7) Wash the blocked membrane with milk using TBST solution. Use 5% BSA liquid to dilute the primary antibody according to the dilution ratio specified in the antibody manual to prepare the required antibody. Then place the PVDF membrane in TBST on a wet box for primary antibody incubation, and place the wet box in a 4°C refrigerator overnight to incubate the primary antibody;
[0128] (8) Remove the wet box and wash the membrane three times with TBST on a shaker for 5 minutes each time. Select different secondary antibodies according to the instructions for the primary antibody. Place the washed membrane on the wet box again and add the secondary antibody liquid and block at room temperature for two hours;
[0129] (9) Expose the target band using a gel imager.
[0130] like Figure 2 The experimental results show that the compound TA-N has a good degradation effect on PLK1 in the HCT116 cell line, and TA-N promotes the degradation of PLK1 protein in a dose- and time-dependent manner. TA-N has shown the ability to degrade PLK1 at 1μM, with obvious degradation occurring around 12h, and can continue to degrade for 48h.
[0131] In general, the present invention detected the killing effect of TA-PROTACs on CRC cells through CCK8 experiments and intracellular Western Blot and evaluated the degradation effect on PLK1, and finally found a small molecule degrader TA-N that has both anti-CRC activity and PLK1 protein degradation ability. This compound has strong activity against CRC and provides a new treatment method for CRC treatment.
Claims
1. A PROTACs based on Tubocapsenolide A, characterized in that The general formula of PROTACs based on TubocapsenolideA is shown in Formula I: Wherein, m is an integer between 0 and 10; L is selected from any of the following structures: E3 is the E3 ubiquitin ligase ligand.
2. The PROTACs based on Tubocapsenolide A according to claim 1, characterized in that The E3 ubiquitin ligase ligand is selected from one or more ligands corresponding to CRBN, VHL, MDM2 and cIAP; Wherein, the CRBN is one of the following structural formulas: W is selected from one of CH2, C=O, SO2, NH and N-alkyl; the alkyl is C1-C4 alkyl; X is selected from one of O and S; Z is selected from one of hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl and halogen; G and G' are each independently selected from H, C1-C4 alkyl, -OH and C1-C4 alkyl substituted 5-10 membered heterocyclic group, wherein the heterocyclic group contains 1-3 heteroatoms of N, O or S; R 1 One selected from H, D, halogen, nitro, amino, cyano, hydroxyl, C1-C4 alkyl, halogenated C1-C4 alkyl and deuterated C1-C4 alkyl; The structural formula of the VHL is: in: R 2 One selected from CH3 and H; The structural formula of the MDM2 is: in: R 3 It is a piperazinyl group, a piperidinyl group, a heterocyclic group or one of the following linking groups: In the linking group, n is an integer of 0-10; The heterocyclic group is piperazinyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl; The structure of the cIAP is:
3. The PROTACs based on Tubocapsenolide A according to claim 2, characterized in that The general formula of the PROTACs based on Tubocapsenolide A is selected from Formula II, Formula III, Formula IV and Formula V: Wherein, m is an integer between 0 and 10; and n is an integer between 0 and 10.
4. The PROTACs based on Tubocapsenolide A according to claim 3, characterized in that Specifically selected from the following compounds:
5. The method for preparing PROTACs based on Tubocapsenolide A according to any one of claims 1 to 4, characterized in that: The route looks like this: Wherein, m is an integer between 0 and 10, and n is an integer between 0 and 10; The following steps are involved: (1) Synthesis of TA-ester TA, 6-heptynoic acid, EDCI and DMAP are added to dichloromethane and reacted at room temperature; after the reaction is completed, dichloromethane is added to the reaction system, extracted, the organic phase is concentrated, and the TA-ester is purified by vacuum distillation; (2) Synthesis of N3-L-E3 a. Synthesis of N3-L-VH032: Compound VH032 was placed in a reaction flask, dichloromethane was added, and then DIPEA, EDCI, and HOBt were reacted under ice bath conditions for 30 minutes, and then the reaction was continued at room temperature. After the reaction was completed by thin layer chromatography, the organic phase was extracted and concentrated, and the organic phase was purified by vacuum distillation to obtain N3-L-VH032. b. Synthesis of N3-L-Pomalidomide: The compound Pomalidomide was dissolved in DMF, and DIPEA was added to the reaction system. The reaction was carried out at 90°C until the reaction was complete, and the organic phase was extracted and concentrated, and the compound N3-L-Pomalidomide was obtained by distillation under reduced pressure and purification; c. Synthesis of N3-L-Nutlin-3: Dissolve Nutlin-3 in DCM, add EDCI, HOBt, DIPEA under ice bath, then add The reaction was completed, and the organic phase was extracted and concentrated, and the compound N3-L-Nutlin-3 was obtained by distillation under reduced pressure and purification; d. Synthesis of N3-L-MeBS: Dissolve MeBS in DCM, add EDCI, HOBt, DIPEA under ice bath, then add The reaction was continued until the reaction was complete, and the organic phase was extracted and concentrated, and the compound N3-L-MeBS was obtained by distillation under reduced pressure and purification; (3) Synthesis of TA-E3 TA-ester and N3-L-E3 prepared in step (2) are dissolved in THF, and then H2O, CuSO4 and sodium L-ascorbate are added to the reaction system, and the reaction is carried out at room temperature; after the reaction is completed by TLC detection, THF is removed by distillation under reduced pressure, dichloromethane is added to the residue, the organic phase is washed with H2O, the organic phase is collected, and dried over anhydrous Na2SO4; the crude product is purified by silica gel column chromatography to obtain the PROTACs based on TubocapsenolideA.
6. The method for preparing PROTACs based on Tubocapsenolide A according to claim 5, characterized in that In the step (1), the molar ratio of TA:6-heptynoic acid:EDCI:DMAP is 1:(1.1-1.3):2:(0.04-0.06); In the step (2), in molar ratio, More like Morby, More like Morby, More like Morby, In the step (3), TA-ester: N3-L-E3: CuSO4: L-sodium ascorbate = 1: (1.1-1.3): (1.1-1.3): (2.5-3.5), and the volume ratio of THF to H2O is 1:
1.
7. A pharmaceutical composition comprising the PROTACs based on Tubocapsenolide A according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof and one or more of a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
8. The pharmaceutical composition according to claim 7, characterized in that The dosage form of the pharmaceutical composition is injection, tablet or capsule.
9. Use of PROTACs based on Tubocapsenolide A according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 7 in the preparation of a drug for treating and / or preventing cancer.
10. The use according to claim 9, characterized in that: The cancer is one or more of colorectal cancer, bone cancer, lung cancer, gastric cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, bladder cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and skin cancer.
